- Home
- SPKL vs IPHA Comparison
SPKL vs IPHA Comparison
Compare SPKL & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPKL
- IPHA
- Stock Information
- Founded
- SPKL 2021
- IPHA 1999
- Country
- SPKL United States
- IPHA France
- Employees
- SPKL N/A
- IPHA N/A
- Industry
- SPKL
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SPKL
- IPHA Health Care
- Exchange
- SPKL Nasdaq
- IPHA Nasdaq
- Market Cap
- SPKL 170.5M
- IPHA 191.0M
- IPO Year
- SPKL 2023
- IPHA 2019
- Fundamental
- Price
- SPKL $10.49
- IPHA $2.23
- Analyst Decision
- SPKL
- IPHA Strong Buy
- Analyst Count
- SPKL 0
- IPHA 1
- Target Price
- SPKL N/A
- IPHA $11.50
- AVG Volume (30 Days)
- SPKL 28.5K
- IPHA 6.6K
- Earning Date
- SPKL 01-01-0001
- IPHA 09-12-2024
- Dividend Yield
- SPKL N/A
- IPHA N/A
- EPS Growth
- SPKL N/A
- IPHA N/A
- EPS
- SPKL 0.12
- IPHA N/A
- Revenue
- SPKL N/A
- IPHA $36,202,722.00
- Revenue This Year
- SPKL N/A
- IPHA N/A
- Revenue Next Year
- SPKL N/A
- IPHA $105.84
- P/E Ratio
- SPKL $85.90
- IPHA N/A
- Revenue Growth
- SPKL N/A
- IPHA N/A
- 52 Week Low
- SPKL $10.07
- IPHA $1.81
- 52 Week High
- SPKL $11.35
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- SPKL 69.74
- IPHA 44.65
- Support Level
- SPKL $10.45
- IPHA $2.22
- Resistance Level
- SPKL $10.49
- IPHA $2.35
- Average True Range (ATR)
- SPKL 0.00
- IPHA 0.13
- MACD
- SPKL 0.00
- IPHA -0.01
- Stochastic Oscillator
- SPKL 80.20
- IPHA 20.59
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.